Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Pazzaglia M., Ghetti E., Stacul F., Tosti A.
Università degli Studi - Bologna Dipartimento di Medicina Clinica Specialistica e Sperimentale Sezione di Clinica Dermatologica (Direttore: Prof. C. Varotti)
Background. Seborrheic dermatitis of the scalp is characterized by scaly, reddish lesions. The aetiological role of Pityrosporum ovale (Malassezia furfur) in seborrheic dermatitis is now supported by results from several studies. Several shampoos and lotions have been developed and marketed as active against dandruff. Ciclopiroxolamine is a substituted pyridone antimycotic unrelated to the imidazole derivatives, with activity against a broad spectrum of dermatophytes, yeasts, actinomycetes, molds, other fungi and a varriety of Gram- positive and Gram- negative bacteria. The purpose of this study was to determine the therapeutic validity of ciclopiroxolamine 1% shampoo (Stiprox®) in patients with mild or moderate seborrheic dermatitis of the scalp.
Methods. In this study, from January to May 1998, twenty-one patients with mild or moderate seborrheic dermatitis of the scalp (8 males and 13 females aged 15-63) were treated with ciclopiroxolamine 1% shampoo for 6 weeks.
Results. Twenty of 21 patients with mild or moderate seborrheic dermatitis of the scalp were cured. No side-effects related to treatment were observed.
Conclusions. Ciclopiroxolamine 1% shampoo showed in our trial a good therapeutic validity for patients with seborrheic dermatitis of the scalp. Ciclopiroxolamine 1% shampoo can be considered an effective and safe shampoo for the treatment of mild or moderate seborrheic dermatitis of the scalp.